Navigation Links
VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
Date:2/25/2009

SAN FRANCISCO, Feb. 25 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis. This patent is also pending in other major markets worldwide.

VIA-2291, which is currently in Phase II development for the treatment of cardiovascular disease caused by atherosclerosis, targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis. A growing body of scientific evidence and data from the VIA-2291 clinical program points to reduction of inflammation and inflammatory processes in the vessel wall as a critical step in combating cardiovascular disease and its complications, including heart attack and stroke.

"Our clinical trial results presented at the most recent meeting of the American Heart Association in New Orleans provides important evidence for VIA-2291's effect on reducing vascular inflammation. This patent is an important step in the commercial development of the compound by providing VIA with exclusivity in this very large and underserved market through 2026," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "We are pleased with the issuance of this important patent as it further strengthens and builds on our existing intellectual property protection for our lead clinical compound."

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candida
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... PHILADELPHIA, Dec. 15 The Center ... Advanstar Communications, is pleased to announce the ... Pharmaceutical/Biotech Accounting and Reporting Congress . The ... Philadelphia, on March 16-17, 2010. ,, Over ... professionals have attended this premier event since ...
(Date:12/15/2009)... December 15 , ... to Evaluate the Ability of,Cardiopoietic Cells to Restore ... BioSciences, a leading Belgian biotechnology company specialising,in cell-based ... that it has completed, two months ahead of ... Phase II/III trial of C-Cure, a,unique stem cell ...
(Date:12/14/2009)... 14 Vermillion, Inc. (Pink Sheets: ... William C. Wallen, Ph.D. Chief Scientific Officer, ... IDEXX Laboratories, will be joining its board ... plan. ,, "Bill brings more than ... diagnostics and biotechnology," said Gail Page, Vermillion ...
(Date:12/14/2009)... -- The third edition of Infusion ... published by the Infusion Nurses Society (INS), includes ... Anthracyclines are a group of chemotherapy medications ... been used in the treatment of various types ... ,, According to the INS publication: "In September ...
Breaking Biology Technology:CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5
... SAN DIEGO, May 19 Sangart, Inc., a ... and,commercialization of therapeutic oxygen transport agents today announced,that ... III trial of its lead,product, Hemospan(R)., Sangart ... to be available in,the second half of 2008., ...
... deliver first open source infectious disease ... management system to meet CDC mandate, PORTLAND, ... brings like-minded organizations,together to work on collaborative software at a ... open source, web-based infectious,disease reporting and management system., The ...
... Medical Technology Distributors ... in 2007., PLEASANTON, Calif., May 19 Direct ... a distribution network covering all,of Russia. This partnership has ... and volume sales to a number of medical,providers in ...
Other Biology Technology:Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent 2Collaborative Software Initiative Addresses State Governments' Requirements for Meeting Infectious Disease Compliance 2Collaborative Software Initiative Addresses State Governments' Requirements for Meeting Infectious Disease Compliance 3Collaborative Software Initiative Addresses State Governments' Requirements for Meeting Infectious Disease Compliance 4Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the World's Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound. 2
(Date:12/15/2009)... Economics, environmental impacts, social dynamics, and production levels ... success of an agroecosystem. Positive or negative, these ... and social groups to continuously adapt farming and ... Experiential learning theory suggests that knowledge is gained ... lessons are especially valuable for environmental and agricultural ...
(Date:12/15/2009)... and ancient American horses may have been grazing ... longer than previously thought. After plucking ancient DNA ... of researchers used cutting-edge techniques to uncover "genetic ... dated to between 7,600 and 10,500 calendar years. ... population of these now-extinct mammals endured longer in ...
(Date:12/15/2009)... This release is available in German ... use in predicting the future distribution of mammals. This ... niches of 140 indigenous European mammals. The researchers analysed ... as well as the phylogenetic information of the species. ... for closely related species, mammals seem to adapt fast ...
Breaking Biology News(10 mins):Experiential learning teaches change and adaptation 2Late-surviving megafauna exposed by ancient DNA in frozen soil 2Late-surviving megafauna exposed by ancient DNA in frozen soil 3Late-surviving megafauna exposed by ancient DNA in frozen soil 4Species distribution models are of only limited value for predicting future mammal distributions 2Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc and Life Technologies Corporation 55977 1Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc and Life Technologies Corporation 55977 2Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc and Life Technologies Corporation 55977 3Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc and Life Technologies Corporation 55977 4Blanchette Rockefeller Neurosciences Institute to Collaborate with Top Brain Injury Group 55972 1Blanchette Rockefeller Neurosciences Institute to Collaborate with Top Brain Injury Group 55972 2Blanchette Rockefeller Neurosciences Institute to Collaborate with Top Brain Injury Group 55972 3Renowned Grief Recovery Experts Now Blogging on Psychology Today 55967 1Renowned Grief Recovery Experts Now Blogging on Psychology Today 55967 2
... new variant of the bird flu virus H5N1 emerged in ... a large part of southern China, despite an ongoing program ... Hong Kong in collaboration with scientists at St. Jude Children's ... to be responsible for the increased occurrence of H5N1 poultry ...
... In the first large-scale analysis of proteins in the ... novel proteins and mechanisms that may one day lead ... results, reported in the current issue of Molecular Psychiatry, ... 50 proteins and point to profound changes in brain ...
... an animal's immune response to the 1918 influenza virus ... supported scientists in an article appearing online today in ... that the 1918 virus triggers a hyperactive immune response ... Furthermore, their results suggest that it is the ...
Other Biology News:Control measures fail to stop spread of new H5N1 virus 2High-tech research shows cocaine changes proteins and brain function 2Mouse study reveals new clues about virulence of 1918 influenza virus 2Mouse study reveals new clues about virulence of 1918 influenza virus 3